c-RET
Os inibidores de c-RET têm como alvo o proto-oncogene RET (Rearranged during Transfection), que codifica uma tirosina quinase receptora envolvida no crescimento, diferenciação e sobrevivência celular. A ativação anormal da sinalização RET pode levar à proliferação celular descontrolada e à resistência à apoptose, contribuindo para o desenvolvimento de cânceres como o carcinoma medular da tireoide e o câncer de pulmão de células não pequenas. A inibição de c-RET pode induzir apoptose em células cancerígenas e é uma abordagem promissora na terapia oncológica direcionada. Na CymitQuimica, oferecemos uma variedade de inibidores de c-RET de alta qualidade para apoiar sua pesquisa em oncologia, transdução de sinais e apoptose.
Foram encontrados 64 produtos para "c-RET".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Fórmula:C5H5N5Pureza:99.02%Cor e Forma:SolidPeso molecular:135.13SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Fórmula:C16H15N5Pureza:99.53%Cor e Forma:SolidPeso molecular:277.32Ref: TM-T16923
1mg46,00€5mg90,00€1mL*10mM (DMSO)90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Fórmula:C16H16ClN3O3Cor e Forma:SolidPeso molecular:333.77Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFórmula:C27H32FN9O2Pureza:97.88% - 99.89%Cor e Forma:White SolidPeso molecular:533.6WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Fórmula:C16H15N3O3Pureza:99.21%Cor e Forma:White SolidPeso molecular:297.31AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Cor e Forma:SolidPeso molecular:473.43Ref: TM-T4301
1mg44,00€1mL*10mM (DMSO)90,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Fórmula:C23H33NaO5Pureza:99.67% - >99.99%Cor e Forma:SolidPeso molecular:412.5GSK3179106
CAS:GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFórmula:C22H21F4N3O4Pureza:99.8% - 99.90%Cor e Forma:SolidPeso molecular:467.41Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Fórmula:C29H31N7O3Pureza:99.87% - >99.99%Cor e Forma:White SolidPeso molecular:525.6Ref: TM-T8222
10mgA consultar25mgA consultar50mgA consultar100mgA consultar200mgA consultar500mgA consultar2mg34,00€5mg49,00€1mL*10mM (DMSO)56,00€RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Fórmula:C19H16N6OPureza:97.94% - 99.62%Cor e Forma:White SolidPeso molecular:344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Fórmula:C28H30F3N7O3Pureza:99.57%Cor e Forma:White SolidPeso molecular:569.58RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Fórmula:C31H29F3N8O2Cor e Forma:SolidPeso molecular:602.61RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C30H29N7Cor e Forma:SolidPeso molecular:487.6RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Fórmula:C29H31F3N6O4Cor e Forma:SolidPeso molecular:584.59DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Fórmula:C19H16N6OPureza:98.03%Cor e Forma:SolidPeso molecular:344.37XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Fórmula:C29H29F3N4OCor e Forma:SolidPeso molecular:506.56RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H30N6O3Cor e Forma:SolidPeso molecular:486.57RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Fórmula:C30H30F3N5O4Cor e Forma:SolidPeso molecular:581.59RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H28N8O2Cor e Forma:SolidPeso molecular:496.56TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Fórmula:C29H31F3N8OPureza:98%Cor e Forma:SolidPeso molecular:564.6
